ClinicalTrials.gg
CompletedNCT03725072Updated Jul 7, 2020

Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib

A Phase 1 interventional study of Evobrutinib in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-07.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of the study is to determine the absorption, metabolism, and excretion of [14C]-evobrutinib in healthy participants

02

Conditions studied

  • Healthy

Keywords

  • [14C]-evobrutinib
  • Healthy
  • Pharmacokinetics
  • Metabolism
  • Excretion
03

In context

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring
  • Have a body weight within 50.0 to 120.0 kilogram (kg) (inclusive) and within the range 19.0 - 30.0 kilogram per meter square (kg/m\^2) (inclusive)
  • Male participants agree to be consistent with local regulations on methods
  • Can give signed
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • History or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders
  • Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery
  • Any surgical or medical condition which might significantly alter the ADME of drugs
  • History of any , chronic or recurrent acute infection
  • History of shingles
  • History of drug ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients
  • History of alcoholism or drug abuse
  • History of residential exposure to tuberculosis, or a positive QuantiFERON test at screening
  • Administration of or live-attenuated virus vaccines
  • Any condition, including findings in the laboratory tests, medical history, or other screening assessments, that in the opinion of the Investigator constitutes an inappropriate risk or a for participation in the study or that could interfere with the study's objectives, conduct, or evaluation
  • Prior/concomitant therapy
  • Relevant radiation exposure
  • Clinically relevant findings (excluding minor deviations) in biochemistry, hematology, coagulation and urinalysis
  • Vital signs (pulse rate and blood pressure) outside the normal range
  • Estimated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
  • Semi supine systolic blood pressure (SBP) greater than (>) 140 millimeters of Mercury (mmHg) or less than (\<) 90 mmHg, diastolic blood pressure (DBP) > 90 mmHg or \< 45 mmHg and pulse rate >= 100 bpm or =\< 40 bpm, at admission
  • 12-Lead (ECG) showing a > 450 millisecond (ms), PR > 215 ms, or QRS > 120 ms
  • Positive for surface antigen (HBsAg), hepatitis B core antibody, antibody, or (HIV) I and II tests at screening
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Evobrutinib

    Drug: Evobrutinib

Interventions

  • Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.

    Also known as: M2951

06

What researchers measure

Primary outcomes

  1. Total Radioactivity Recovery Rate of Evobrutinib, Total Radioactivity and its Metabolites

    Time frame: Pre-dose up to Day 35 post-dose

  2. Percentage Excretion of Evobrutinib, Total Radioactivity and its Metabolites in Urine and Feces

    Time frame: Pre-dose up to Day 35 post-dose

  3. Renal Clearance of Evobrutinib, Total Radioactivity and its Metabolites

    Time frame: Pre-dose up to Day 35 post-dose

  4. Maximum Observed Plasma Concentration (Cmax) of Total [14C] Radioactivity (Evobrutinib and Metabolites)

    Time frame: Pre-dose up to Day 35 post-dose

  5. Time to Reach Maximum Plasma Concentration (Tmax) of Total [14C] Radioactivity (Evobrutinib and Metabolites)

    Time frame: Pre-dose up to Day 35 post-dose

  6. Terminal Elimination Half-Life (t1/2) of Total [14C] Radioactivity (Evobrutinib and Metabolites)

    Time frame: Pre-dose up to Day 35 post-dose

  7. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Total [14C] Radioactivity (Evobrutinib and Metabolites)

    Time frame: Pre-dose up to Day 35 post-dose

  8. Maximum Observed Plasma Concentration (Cmax) of Evobrutinib

    Time frame: Pre-dose up to Day 35 post-dose

  9. Time to Reach Maximum Plasma Concentration (Tmax) of Evobrutinib

    Time frame: Pre-dose up to Day 35 post-dose

  10. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Evobrutinib

    Time frame: Pre-dose up to Day 35 post-dose

  11. Terminal Elimination Half-Life (t1/2) of Evobrutinib

    Time frame: Pre-dose up to Day 35 post-dose

  12. Apparent Volume of Distribution During Terminal Phase (Vz/f) of Evobrutinib

    Time frame: Pre-dose up to Day 35 post-dose

  13. Apparent Clearance (CL/f) of Evobrutinib

    Time frame: Pre-dose up to Day 35 post-dose

Secondary outcomes

  1. Number of Participants with Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings

    Number of participants with clinically significant abnormalities will be reported.

    Time frame: From time of first dose to end of study participation approximately at Day 37

  2. Occurrence of Treatment -emergent Adverse Events (TEAEs) and Serious TEAEs

    Time frame: From time of first dose to end of study participation approximately at Day 37

  3. Occurrence of Treatment -emergent Adverse Events (TEAEs) and Serious TEAEs by Severity

    Time frame: From time of first dose to end of study participation approximately at Day 37

07

Study locations

1 site
  • PRA Health Sciences
    Groningen, 9728 NZ, Netherlands
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Dec 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2018
First posted
Oct 30, 2018
StartActual
Oct 30, 2018
Primary completionActual
Dec 5, 2018
CompletionActual
Dec 5, 2018
Last update
Jul 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03725072
Responsible party
Sponsor
First posted
Oct 30, 2018
Start date
Oct 30, 2018
Primary completion
Dec 5, 2018
Completion
Dec 5, 2018
Last update
Jul 7, 2020

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion